在患有慢性阻塞性肺疾病（COPD）的吸烟者中，与尼古丁替代疗法（NRT）相比，伐尼克兰和安非他酮均未显示出增加心血管（CV）或神经精神风险的关联。 - Suppr | 超能文献

In smokers with COPD, neither varenicline nor bupropion was linked to increased CV or neuropsychiatric risk vs NRT.

作者信息

Kress Catherine M, Obi Ngozi U, Prochazka Allan V

出版信息

Ann Intern Med. 2017 Sep 19;167(6):JC31. doi: 10.7326/ACPJC-2017-167-6-031.

DOI:10.7326/ACPJC-2017-167-6-031

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

In smokers with COPD, neither varenicline nor bupropion was linked to increased CV or neuropsychiatric risk vs NRT.在患有慢性阻塞性肺疾病（COPD）的吸烟者中，与尼古丁替代疗法（NRT）相比，伐尼克兰和安非他酮均未显示出增加心血管（CV）或神经精神风险的关联。

Ann Intern Med. 2017 Sep 19;167(6):JC31. doi: 10.7326/ACPJC-2017-167-6-031.

2

Characteristics of COPD smokers and effectiveness and safety of smoking cessation medications.COPD 吸烟者的特征及戒烟药物的有效性和安全性。

Nicotine Tob Res. 2012 Sep;14(9):1035-9. doi: 10.1093/ntr/nts001. Epub 2012 Feb 17.

3

Smoking cessation treatment for COPD smokers: the role of pharmacological interventions.慢性阻塞性肺疾病吸烟者的戒烟治疗：药物干预的作用

Monaldi Arch Chest Dis. 2013 Mar;79(1):27-32. doi: 10.4081/monaldi.2013.106.

4

Did the introduction of varenicline in England substitute for or add to the use of other smoking cessation medications?在英国，引入伐伦克林是否替代或增加了其他戒烟药物的使用？

Nicotine Tob Res. 2011 Sep;13(9):793-9. doi: 10.1093/ntr/ntr075. Epub 2011 May 4.

5

Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.在芬兰成年烟民队列中，比较伐伦克林、安非他酮与未辅助戒烟对戒烟的成本效果。

Curr Med Res Opin. 2010 Mar;26(3):549-60. doi: 10.1185/03007990903542666.

6

Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease.慢性阻塞性肺疾病吸烟者中伐伦克林和安非他酮的心血管和神经精神风险。

Thorax. 2017 Oct;72(10):905-911. doi: 10.1136/thoraxjnl-2017-210067. Epub 2017 May 4.

7

Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.伐尼克兰与安非他酮、尼古丁替代疗法及尼加拉瓜无辅助戒烟的成本分析。

Hosp Pract (1995). 2012 Feb;40(1):35-43. doi: 10.3810/hp.2012.02.946.

8

Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.希腊伐伦克林与安非他酮、尼古丁替代疗法和非药物戒烟的成本效益比较。

Clin Ther. 2012 Aug;34(8):1803-14. doi: 10.1016/j.clinthera.2012.07.002. Epub 2012 Jul 20.

9

Neuropsychiatric safety of varenicline in the general and COPD population with and without psychiatric disorders: a retrospective cohort study in a real-world setting.在一般人群和伴有或不伴有精神障碍的 COPD 人群中，伐伦克林的神经精神安全性：真实环境下的回顾性队列研究。

BMJ Open. 2021 May 25;11(5):e042417. doi: 10.1136/bmjopen-2020-042417.

10

Smoking cessation.戒烟。

Clin Chest Med. 2014 Mar;35(1):165-76. doi: 10.1016/j.ccm.2013.11.002.

引用本文的文献

1

Risk of neuropsychiatric adverse events associated with varenicline treatment for smoking cessation among Dutch population: A sequence symmetry analysis.与荷兰人群戒烟用伐伦克林治疗相关的神经精神不良事件风险：序列对称分析。

Pharmacoepidemiol Drug Saf. 2022 Feb;31(2):158-166. doi: 10.1002/pds.5351. Epub 2021 Sep 9.